midodrine has been researched along with Prostatic Neoplasms in 1 studies
Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Shim, M | 1 |
Kim, J | 1 |
Park, S | 1 |
Choi, SK | 1 |
Lee, SM | 1 |
Huh, KO | 1 |
Song, C | 1 |
Choo, MS | 1 |
Ahn, H | 1 |
1 trial available for midodrine and Prostatic Neoplasms
Article | Year |
---|---|
The therapeutic effect of solifenacin succinate on the recovery from voiding dysfunction after radical prostatectomy in men with clinically localized prostate cancer: a prospective, randomized, controlled study.
Topics: Adrenergic alpha-1 Receptor Agonists; Aged; Drug Therapy, Combination; Humans; Male; Midodrine; Musc | 2015 |